We have often heard that a new male contraceptive is ‘five to
ten years’ away. But are we getting any closer? Tom Pritchard weighs up
the latest research.
Well, two recent announcements indicate the growing interest drug companies
are showing in the subject and highlight the problems researchers face. Scientists
in Europe and the US have found one hot new lead in the quest to find an effective
male contraceptive, but a once promising study has been relegated to the ‘has-been’
of scientific research.
A door opens
Men - would you take the male 'pill', or are the health
concerns too great?
Women - would you trust your partner to take the lead in
family planning? Discuss this topic and more on our Message
Forums |
Researchers in Italy and at the Population Council in New York have announced
a breakthrough on a non-hormonal compound known as Adjudin. By injecting the
compound as an attachment to a modified hormone that seeks out the testes, researchers
have found that a low dose is both safe and effective in rats. Without this
targeting mechanism, only much higher doses are effective - but they are harmful
to the body's organs.
Dr. Diana Blithe of the U.S. National Institutes of Health, a long-time funder
of the Adjudin research, says that "This [new breakthrough] is what they
were looking for and it looks like it's working."
The next step is to find a more appealing delivery system than shots; both
a gel and a matchstick-sized implant have been discussed.
But will the contraceptive work as well in humans as in rats? Nothing is guaranteed.
Elaine Lissner, director of the nonprofit Male Contraception Information Project,
says the public gets frustrated because media reports make it sound as if every
advance means a new contraceptive lies right around the corner. "People
really need to distinguish between research in animals - or even in a lab dish--and
studies in men."
Adjudin study coauthor Dr. Yan Cheng agrees, and says dedication will be required.
"Obviously we're quite excited--but we still have a lot of work to do and
a lot of hurdles to overcome."
A door closes
The latest promising contraceptive that didn't make the leap from mice to men
is miglustat (trade name Zavesca). The drug is already approved and on the market
in both Europe and the United States for treatment of a rare genetic disorder
known as Gaucher disease. Given that the drug has been tested and deemed safe,
it was only natural that scientists were very excited when they realised that
it was acting as a contraceptive in their male mice at a tenth of the disease-treatment
dose.
With safety testing already out of the way, they thought this male ‘Pill’
could potentially be brought to market very quickly.
Because of the growing public interest in male contraceptives, researcher Dr.
John Amory at the University of Washington, Seattle was able to obtain funding
to test the drug's effect in seven healthy men.
The result? Nothing - no effect on fertility, even at a dose high enough to
cause diarrhoea, stomach upset, and other unpleasant side effects. A round-about
way of male contraception we suppose!
"We knew it was going to be either a strike out or a home run," says
Amory. "It was a big disappointment."
Unbeknownst to Amory, pharmaceutical giant Schering was simultaneously testing
miglustat in rabbits and another strain of mice, and found the same results
- contraception in the first strain of mice, but no effect in the other strain
or other species.
The original studies used C57 Black/6 mice, the most common strain of laboratory
mouse.
Dr. Aarnoud van der Spoel, research associate in the department of pharmacology
at the University of Oxford and an author of those early studies, confirms that
the mouse strain is somehow different. He has now tested multiple strains of
mice and found some effect, but not enough to produce infertility.
"Biology is full of surprises. Clearly in the case of miglustat, a man
is not a mouse," he adds.
What Next?
So with Adjudin showing positive results - but only after tests on rats - and
miglustat no longer an option, will men see a new contraceptive in the near
future?
"The trick is to make sure we follow up on the leads we have," says
Lissner. "There's a tendency to support glamorous new research in the lab,
but abandon it when it gets to the expensive part: actually testing it on men
and getting it to market."
This problem of moving leads from the lab to human studies affects all types
of contraceptive research. Michael Free, vice president and senior advisor for
technologies at Seattle-based non-profit PATH, points to the female condom as
an example.
"We got funding to design a great female condom that men and women like
much better than what's out there," he says. "But now we're ready
to do the big clinical trials, and our funders just don't have the money."
But change may be in the air. Lissner cites the recently opened Intra Vas Device
trial as proof. The long-term male contraceptive is being developed by a startup
company, supported by a small U.S. National Institutes of Health grant. Due
to popular demand, the trial has been expanded to four U.S. cities and can accept
90 participants. Similar approaches have been shown to work in men in studies
in China and India.